CN102480956B - 吡啶并[4,3-b]吲哚类和使用方法 - Google Patents

吡啶并[4,3-b]吲哚类和使用方法 Download PDF

Info

Publication number
CN102480956B
CN102480956B CN201080029084.1A CN201080029084A CN102480956B CN 102480956 B CN102480956 B CN 102480956B CN 201080029084 A CN201080029084 A CN 201080029084A CN 102480956 B CN102480956 B CN 102480956B
Authority
CN
China
Prior art keywords
substituted
compound
compounds
unsubstituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080029084.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102480956A (zh
Inventor
R·P·贾殷
S·查克拉瓦蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Technologies LLC
Original Assignee
Medivation Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies LLC filed Critical Medivation Technologies LLC
Publication of CN102480956A publication Critical patent/CN102480956A/zh
Application granted granted Critical
Publication of CN102480956B publication Critical patent/CN102480956B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201080029084.1A 2009-04-29 2010-04-29 吡啶并[4,3-b]吲哚类和使用方法 Expired - Fee Related CN102480956B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1135MU2009 2009-04-29
IN1135/MUM/2009 2009-04-29
US18125909P 2009-05-26 2009-05-26
US61/181,259 2009-05-26
PCT/US2010/033055 WO2011019417A1 (en) 2009-04-29 2010-04-29 Pyrido [4, 3-b] indoles and methods of use

Publications (2)

Publication Number Publication Date
CN102480956A CN102480956A (zh) 2012-05-30
CN102480956B true CN102480956B (zh) 2015-04-08

Family

ID=43586371

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080029084.1A Expired - Fee Related CN102480956B (zh) 2009-04-29 2010-04-29 吡啶并[4,3-b]吲哚类和使用方法

Country Status (8)

Country Link
US (2) US8741919B2 (enExample)
EP (1) EP2424366B1 (enExample)
JP (1) JP5827943B2 (enExample)
CN (1) CN102480956B (enExample)
AU (1) AU2010282990B2 (enExample)
BR (1) BRPI1006608A2 (enExample)
CA (1) CA2760516A1 (enExample)
WO (1) WO2011019417A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔３，４－ｂ〕吲哚及使用方法
TWI450900B (zh) 2008-03-24 2014-09-01 Medivation Technologies Inc 橋聯雜環化合物及使用方法
AR073923A1 (es) 2008-10-31 2010-12-09 Medivation Technologies Inc Pirido( 4,3-b) indoles que contienen restos rigidos
CN102316732B (zh) 2008-10-31 2015-04-01 梅迪维新技术公司 氮杂*并[4,5-b]吲哚以及使用方法
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9095572B2 (en) * 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2748813C (en) 2009-01-09 2018-07-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010214101A1 (en) 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
WO2010127177A1 (en) * 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido [4,3-b] indoles and methods of use
WO2011019417A1 (en) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
WO2011038161A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
CN102711466A (zh) 2009-09-23 2012-10-03 梅迪维新技术公司 桥连杂环化合物及其使用方法
AU2010298168B2 (en) 2009-09-23 2015-11-19 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
US20140155384A1 (en) 2011-02-18 2014-06-05 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
CA2829045A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
EP2785720B1 (en) * 2011-11-29 2017-08-09 Nanjing Allgen Pharma Co. Ltd. Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents
WO2014031167A1 (en) * 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
EP2887803A4 (en) 2012-08-24 2016-08-03 Univ Texas PRO-NEUROGENIC COMPOUNDS
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
MX2020008237A (es) 2018-02-05 2020-09-25 Univ Rockefeller Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
EP4216940A4 (en) * 2020-09-24 2025-01-01 Ventus Therapeutics U.S., Inc. PYRIDO[4,3-B INDOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087425A1 (en) * 2006-01-25 2007-08-02 Medivation Neurology,Inc. Methods and compositions for treating schizophrenia
CN101268075A (zh) * 2005-07-28 2008-09-17 百时美施贵宝公司 作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
WO2008123796A2 (ru) * 2007-04-05 2008-10-16 Alla Chem, Llc Замещенные 2,3,4,5-tetpaгидpo-1h-пиpидo[4,3-b]иhдoлы, способ их получения и применения

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409628A (en) 1966-05-12 1968-11-05 Hoffmann La Roche 5-(3-pyridylethyl)pyridoindole derivatives
US3484449A (en) 1966-05-12 1969-12-16 Hoffmann La Roche Certain substituted phenyl amino-ethylpyridine intermediates
US3502688A (en) 1968-09-10 1970-03-24 Hoffmann La Roche 5-(4-pyridylethyl)-pyridoindole derivatives
US3646045A (en) 1968-09-10 1972-02-29 Hoffmann La Roche Intermediates for 5-(4-pyridylethyl)-pyridoindole derivatives
JPS5143863B2 (enExample) 1973-06-18 1976-11-25
US4754038A (en) 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
IL91167A (en) 1988-08-02 1993-06-10 Glaxo Group Ltd Substituted 2-(imidazolymethyl)-pyrido- (and azepino-) indol-1-one derivatives, their preparation and pharmaceutical compositions containing them
RU2140417C1 (ru) 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
DE10030375A1 (de) 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
US6849640B2 (en) 2001-08-08 2005-02-01 Pharmacia & Upjohn Company Therapeutic 1H-pyrido [4,3-b] indoles
US7736889B2 (en) 2003-06-10 2010-06-15 The United States Of America As Represented By The Secretary Of The Navy Fluidic force discrimination
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
WO2007041697A2 (en) 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
US20100099700A1 (en) 2006-09-20 2010-04-22 David Hung Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als)
CA2664098A1 (en) 2006-09-20 2008-03-27 Medivation Neurology, Inc. Compounds and method for treating canine cognitive dysfunction syndrome
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2334514C1 (ru) 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2340342C2 (ru) 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2338745C1 (ru) 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
MX2009012788A (es) 2007-05-25 2010-01-14 Medivation Neurology Inc Metodos y composiciones para estimular celulas.
RU2338533C1 (ru) 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
CA2719824A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
AU2008302751A1 (en) 2007-09-20 2009-03-26 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
WO2009039420A1 (en) 2007-09-21 2009-03-26 Medivation Neurology, Inc. Methods and compositions for treating neuronal death mediated ocular diseases
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
EP2236511A4 (en) 2007-12-21 2011-04-13 Alla Chem Llc LIGANDS OF ALPHA ADRENOCEPTORS AND OF DOPAMINE, HISTAMIN, IMIDAZOLIN AND SEROTONIN RECEPTORS AND THEIR APPLICATION THEREOF
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2009111540A1 (en) 2008-03-04 2009-09-11 Medivation Neurology, Inc. Methods for preparing pyridylethyl-substituted carbolines
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔３，４－ｂ〕吲哚及使用方法
TWI450900B (zh) 2008-03-24 2014-09-01 Medivation Technologies Inc 橋聯雜環化合物及使用方法
WO2009135091A1 (en) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
CN101640878B (zh) 2008-07-29 2011-08-31 华为技术有限公司 一种确定漫游用户终端移动性的方法及装置
WO2010014758A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
CN102316732B (zh) 2008-10-31 2015-04-01 梅迪维新技术公司 氮杂*并[4,5-b]吲哚以及使用方法
AR073923A1 (es) * 2008-10-31 2010-12-09 Medivation Technologies Inc Pirido( 4,3-b) indoles que contienen restos rigidos
WO2011019417A1 (en) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
WO2010127177A1 (en) * 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido [4,3-b] indoles and methods of use
WO2011014695A1 (en) 2009-07-29 2011-02-03 Medivation Technologies, Inc. New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use
EP2480079A4 (en) 2009-09-23 2015-04-08 Medivation Technologies Inc PYRIDO- (3,4-B-) INDOLE AND USE METHOD THEREFOR
WO2011038161A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
CN102711466A (zh) 2009-09-23 2012-10-03 梅迪维新技术公司 桥连杂环化合物及其使用方法
AU2010298168B2 (en) 2009-09-23 2015-11-19 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103487A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2011103448A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
CA2829045A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US20140155384A1 (en) 2011-02-18 2014-06-05 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2014031167A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101268075A (zh) * 2005-07-28 2008-09-17 百时美施贵宝公司 作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
WO2007087425A1 (en) * 2006-01-25 2007-08-02 Medivation Neurology,Inc. Methods and compositions for treating schizophrenia
WO2008123796A2 (ru) * 2007-04-05 2008-10-16 Alla Chem, Llc Замещенные 2,3,4,5-tetpaгидpo-1h-пиpидo[4,3-b]иhдoлы, способ их получения и применения

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Modeling of 5-HT2A and 5-HT2C Receptors and of Their Complexes with Actual and Potential Antipsychotic Drugs;Dezi C, et al;《PhD Thesis,Pompeu Fabra University》;20070619;第1-239页 *

Also Published As

Publication number Publication date
HK1171167A1 (en) 2013-03-22
CA2760516A1 (en) 2011-02-17
WO2011019417A1 (en) 2011-02-17
AU2010282990B2 (en) 2015-11-05
AU2010282990A1 (en) 2011-11-17
JP5827943B2 (ja) 2015-12-02
US8927571B2 (en) 2015-01-06
EP2424366A4 (en) 2012-12-19
US8741919B2 (en) 2014-06-03
US20130190331A1 (en) 2013-07-25
BRPI1006608A2 (pt) 2015-08-25
US20120172377A1 (en) 2012-07-05
CN102480956A (zh) 2012-05-30
WO2011019417A8 (en) 2011-12-15
JP2012525431A (ja) 2012-10-22
EP2424366B1 (en) 2016-02-17
EP2424366A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
CN102724875B (zh) 吡啶并[3,4-b]吲哚化合物及其使用方法
CN102480955B (zh) 吡啶并[4,3-b]吲哚类和使用方法
CN102711468B (zh) 吡啶并[4，3-b]吲哚化合物及其使用方法
US8927571B2 (en) Pyrido[4,3-B]indoles and methods of use
JP5586577B2 (ja) 架橋複素環化合物およびその使用
CN101983059B (zh) 2,3,4,5- 四氢 -1h- 吡啶并 [4,3-b] 吲哚化合物及其使用方法
CN102711467A (zh) 吡啶并[3,4-b]吲哚类及使用方法
CN102711466A (zh) 桥连杂环化合物及其使用方法
CN102316732A (zh) 氮杂䓬并[4,5-b]吲哚以及使用方法
CN102083830A (zh) 吡啶并[3，4-b]吲哚和应用方法
HK1171167B (en) Pyrido [4, 3-b] indoles and methods of use
HK1176812A (en) Bridged heterocyclic compounds and methods of use
HK1176814A (en) Pyrido[3,4-b]indoles and methods of use
AU2013203574A1 (en) Pyrido [4,3-b] indoles and methods of use
HK1176811B (en) Pyrido[4,3-b]indoles and methods of use
HK1170380B (en) Pyrido [4,3-b] indoles and methods of use
HK1176813B (en) Pyrido[3,4-b]indoles and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1171167

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1171167

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150408

Termination date: 20170429

CF01 Termination of patent right due to non-payment of annual fee